The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

Overview of attention for article published in Frontiers in Pharmacology, February 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 2 X users

Readers on

mendeley: 16 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,823 followers.

RT @FrontPharmacol: New Research: The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabe…

02 Feb 2022

Reply Repost Favourite

New Research: The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile https://t.co/93PP1Y1buM #pharmacology

02 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.